control group:TKI

2 trials

Sponsors

Affiliated Tumor Hospital of Xinjiang Medical University, Departmen of Radiation Oncology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University

Conditions

Non-small Cell Lung Cancerlung cancer

Early Phase 1

EGFR-TKI Combined With Stereotactic Body Radiation Therapy Versus TKI alone for Stage IV Oncogene-Driven Non-Small Cell Lung Cancer

RecruitingChiCTR1900027030

Departmen of Radiation Oncology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou UniversityNon-small Cell Lung Cancer

Start: 2019-11-01Updated: 2019-11-04

Phase 4

Anlotinib combined with first-generation EGFR-TKI in comparison with TKI alone in patients with advanced NSCLC with EGFR mutation positive and slow progression after TKI therapy

Active, not recruitingChiCTR1800019138

Affiliated Tumor Hospital of Xinjiang Medical Universitylung cancer

Start: 2019-01-01Updated: 2018-11-12